UNSPSC 51111877: Enzalutamide

An androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer.

UNSPSC 51111877 Enzalutamide, a Commodity code, covers pharmaceutical procurement for state and local health benefit programs, specifically the supply of this androgen receptor inhibitor used in prostate cancer treatment. State and local governments acquire enzalutamide primarily through health and human services agencies managing pharmacy benefit programs for state employees, retirees, and Medicaid populations. The procurement activity under this code reflects the operational focus of state health authorities on securing oncology pharmaceuticals through varied contracting channels—traditional pharmacy benefit managers, direct-to-manufacturer relationships, group purchasing organizations, and negotiated net pricing models that emphasize cost management and outcomes-based agreements. Issuing bodies include state health and human services commissions, pharmacy benefit program administrators, and employee health plan offices responsible for formulary management and drug procurement policy. The Texas Health and Human Services Commission represents the primary visible buyer in current activity, pursuing market intelligence on direct-to-manufacturer prescription fulfillment models as an alternative to conventional PBM and GPO channels.

The code shows concentrated recent activity in Texas, where the Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence on direct-to-manufacturer prescription programs under the Therapeutic Pharmacy Initiative. The RFI response deadline was April 3, 2026. This information-gathering solicitation does not establish award value, timeline, or formal competitive criteria; it functions as preliminary market research to inform subsequent formal procurement specifications and pricing models. The agency is gathering vendor responses regarding direct contracting experience with self-insured employers and government health plans, flexibility on negotiated net pricing without rebates, and capability to implement value-based or outcomes-based agreements. No other recent state or local opportunities for enzalutamide under this code are visible in the source material.